Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2Phase 3 Interventional Results available

A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

ClinicalTrials.gov ID: NCT05267600

Public ClinicalTrials.gov record NCT05267600. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

Study identification

NCT ID
NCT05267600
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
argenx
Industry
Enrollment
98 participants

Conditions and interventions

Interventions

  • efgartigimod PH20 SC Biological
  • placebo Other
  • Prednisone Drug

Biological · Other · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 8, 2022
Primary completion
Sep 12, 2024
Completion
Sep 12, 2024
Last update posted
Oct 22, 2025

2022 – 2024

United States locations

U.S. sites
21
U.S. states
16
U.S. cities
21
Facility City State ZIP Site status
Investigator site 74 - US0010178 Phoenix Arizona 85006
Investigator site 6 - US0010138 Fountain Valley California 92708
Investigator site 121 - US0010092 Redwood City California 94063
Investigator site 72 - US0010186 Santa Monica California 90404
Investigator site 10 - US0010153 Castle Rock Colorado 80109
Investigator site 2 - US0010087 Boca Raton Florida 33428
Investigator site 21 - US0010152 Clearwater Florida 33756
Investigator site 1 - US0010017 Miami Florida 33173
Investigator site 13 - US0010155 West Lafayette Indiana 47906
Investigator site 35 - US0010156 Louisville Kentucky 40217
Investigator site 50 - US0010149 Ann Arbor Michigan 48109
Investigator site 115 - US0010157 Jackson Mississippi 39216
Investigator site 73 - US0010098 St Louis Missouri 63110
Investigator site 85 - US0010159 Lebanon New Hampshire 03756
Investigator site 5 - US0010088 Buffalo New York 14203
Investigator site 93 - US0010169 New York New York 10016
Investigator site 4 - US0010137 Fairborn Ohio 45324
Investigator site 25 - US0010158 Pittsburgh Pennsylvania 15213
Investigator site 34 - US0010182 Houston Texas 77004
Investigator site 92 - US0010150 Murray Utah 84107
Investigator site 3 - US0010151 Morgantown West Virginia 26505

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 108 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05267600, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 22, 2025 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05267600 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →